2. Academic Validation
  3. Dopamine receptor antagonists

Dopamine receptor antagonists

  • Ann Palliat Med. 2012 Jul;1(2):137-42. doi: 10.3978/j.issn.2224-5820.2012.07.09.
Howard S Smith 1,  Lorrain R Cox 2,  Benjamin R Smith 3
Affiliations

Affiliations

  • 1 Albany Medical College, Department of Anesthesiology, 47 New Scotland Avenue, MC-131, Albany, New York 12208, USA. [email protected].
  • 2 Palliative Medicine Service, Albany Medical Center Hospital, 47 New Scotland Avenue, Albany, New York, USA.
  • 3 36 Grantwood Road, Delmar, New York, USA.
PMID: 25841474 DOI: 10.3978/j.issn.2224-5820.2012.07.09
Abstract

Intractable nausea and/or vomiting is a serious and significant clinical dilemma that may greatly detract from quality of life. One of the first classes of antiemetic agents used as well as one of the commonest classes of antiemetic agents used is that of the Dopamine Receptor antagonists. Dopamine Receptor antagonists are useful antiemetic agents, however, unfortunately, clinicians have on occasion resorted to switching from one Dopamine Receptor Antagonist to another Dopamine Receptor Antagonist when the initial Dopamine Receptor Antagonist was ineffective rather than adding on a second antiemetic agent from a totally different class (e.g., 5-HT3 receptor antagonists, NK-1 receptor antagonists).

Keywords

Nausea; butyrophenones; dopamine receptor antagonists; metoclopramide; phenothiazines; vomiting.

Figures
Products